https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA Removes REMS for Currently Approved BCMA-, CD19-Directed CAR T Cell Immunotherapies

FDA Removes REMS for Currently Approved BCMA-, CD19-Directed CAR T Cell Immunotherapies

FDA removes REMS for CAR T-cell therapies, enhancing patient access while ensuring safety in cancer treatment.

administrator

Related Articles